Monitoring of Post-Transplant MLL-PTD as Minimal Residual Disease Can Predict Relapse after Allogeneic HSCT in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

Investigators retrospectively collected the clinical data of 48 patients with mixed-lineage leukemia (MLL)-partial tandem duplications (PTD) acute myeloid leukemia or myelodysplastic syndrome with excess blasts who underwent allogeneic hematopoietic stem cell transplantation (HSCT) in Peking University People’s Hospital.